title: PharmGKB summary: very important pharmacogene information for RYR1.
authors.affiliation: Departments of aGenetics bBioengineering, Stanford University, Stanford cChildren's Hospital Oakland Research Institute and UCSF, Oakland, California dDepartment of Medicine, University of North Dakota, Fargo, North Dakota eIMAGENETICS, Sanford Healthcare, Sioux Falls, South Dakota, USA.
authors.forename: Maria L
authors.initials: ML
authors.lastname: Alvarellos
authors.forename: Ronald M
authors.initials: RM
authors.lastname: Krauss
authors.forename: Russell A
authors.initials: RA
authors.lastname: Wilke
authors.forename: Russ B
authors.initials: RB
authors.lastname: Altman
authors.forename: Teri E
authors.initials: TE
authors.lastname: Klein
mesh_terms: D020022:Genetic Predisposition to Disease; D014644:Genetic Variation; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects; D008305:Malignant Hyperthermia / Q000453:epidemiology / Q000235:genetics*; D018482:Muscle, Skeletal / Q000378:metabolism*; D009135:Muscular Diseases / Q000139:chemically induced / Q000235:genetics; D010597:Pharmacogenetics; D019837:Ryanodine Receptor Calcium Release Channel / Q000235:genetics* / Q000378:metabolism
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D019837:Ryanodine Receptor Calcium Release Channel